Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Feagins

Urology Dallas, TX Medical Doctor

NPI 1649229790 CMS profile 29421

10501 N. Central Expressway, Suite 200, Dallas, TX 75231

Open in the dashboard

General payments

$6,999

191 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Feagins of Dallas, TX is reported in the CMS Open Payments database as having received $6,999 across 191 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27 1
2024 General $489 10
2023 General $840 35
2022 General $2,413 44
2021 General $1,492 40
2020 General $726 18
2019 General $1,013 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Feagins
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Brian Feagins were reported at $27. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Brian Feagins Urology median Middle half National median
2019 $1,013 $480 $147–$1,201 $163
2020 $726 $246 $87–$645 $114
2021 $1,492 $358 $111–$1,000 $132
2022 $2,413 $476 $143–$1,263 $149
2023 $840 $560 $168–$1,461 $160
2024 $489 $563 $170–$1,464 $164
2025 $27 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Valencia Technologies Corporation $1,131 4 payments
  2. Caldera Medical, Inc $899 9 payments
  3. Medtronic, Inc. $861 16 payments
  4. Medtronic USA, Inc. $794 10 payments
  5. Astellas Pharma US Inc $690 38 payments
  6. Axonics Modulation Technologies, Inc. $485 13 payments
  7. Boston Scientific Corporation $282 10 payments
  8. Coloplast Corp $159 8 payments
  9. Antares Pharma, Inc. $146 11 payments
  10. AbbVie, Inc. $141 7 payments
  11. Other $1,411 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,855 187 payments
  2. Travel and Lodging $1,064 1 payment
  3. Gift $56 2 payments
  4. Education $24 1 payment
Products named General payments · program years 2019–2025
  1. eCoin Device Kit $1,131 4 payments
  2. Desara $899 9 payments
  3. INTERSTIM Sacral Nerve Stimulation $861 16 payments
  4. INTERSTIM Sacral Nerve Stimulation $794 10 payments
  5. MYRBETRIQ $690 38 payments
  6. Bulkamid $241 4 payments
  7. Axonics $218 7 payments
  8. GEMTESA $176 8 payments
  9. ORGOVYX $134 6 payments
  10. IMVEXXY $129 4 payments
  11. Other $2,122 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

734

Median for Urology: 1,053

Drug cost

$159,557

Median for Urology: $101,464

Branded share of claims

53.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 140 $114,329
Gemtesa Vibegron Brand 34 $31,363
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 70 $3,432
Solifenacin Succinate Generic 38 $2,333
Potassium Citrate Er Potassium Citrate Brand 27 $1,741
Tamsulosin Hcl Generic 129 $1,667
Oxybutynin Chloride Er Oxybutynin Chloride Brand 78 $1,394
Trospium Chloride Er Trospium Chloride Brand 12 $761
Trospium Chloride Generic 11 $731
Fluconazole Generic 18 $287

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$35,196

Medicare's payments for the services billed

Medicare patients

232

Average age 76

Services billed

1,462

138 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 59%
Ischemic heart disease 28%
Osteoporosis 25%
Diabetes 22%
Chronic kidney disease 22%
Depression 22%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $30
$30 34 —
BOTOX
  • AbbVie, Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

191 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record